VOLUNTARY ANNOUNCEMENT - "LENALIDOMIDE CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. (Incorporated in Hong Kong with limited liability) (Stock code: 1093) VOLUNTARY ANNOUNCEMENT “LENALIDOMIDE CAPSULES” OBTAINS DRUG REGISTRATION APPROV AL The board of directors (the “ Board”) of CSPC Pharmaceutical Group Limited (the “ Company”, together with its subsidiaries, the “ Group ”) is pleased to announce that the “Lenalidomide Capsules (25mg)” (the “ Product ”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (ʮ̡), a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs. Lenalidomide is a new generation oral immunomodulatory drug with immunomodulatory, antiangiogenic, and antineoplastic properties. It is used to treat 1) in combination with dexamethasone, adult patients with previously untreated multiple myeloma who are not eligible for transplant; 2) in combination with dexamethasone, adult patients with multiple myeloma who have received at least one prior therapy. The approval of the Product will further enrich the Group’s product portfolio of antineoplastic drugs. By order of the Board CSPC Pharmaceutical Group Limited Cai Dongchen Chairman Hong Kong, 20 September 2022 As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. P AN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors. * For identification purposes only

The release as fetched from its publisher. irasia.com ↗